NN9924-4635
This trial is a 68 week double blind trial evaluating 3 doses of semaglutide in people with type 2 diabetes.

Type of Study:
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in people with type 2 diabetes

Study Length:
68 Weeks

Target Age/Sex:
over 18 years, Male and Female

Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov

Staus: Enrolling

Description:

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in people with type 2 diabetes.

Enroll Now

Enroll Now

Address
Address
City
State/Province
Zip/Postal
If you don't have a primary care physician, just type "Do not have a primary care physician"